Emibe

PRESENTATION:

Emibe 10: Each tablet contains Ezetimibe INN 10 mg.

INDICATION:

Primary Hypercholesterolemia

Emibe 10 co-administered with statin is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia who are not appropriately controlled with a statin alone.

Emibe 10 monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia in whom a statin is considered inappropriate or is not tolerated.

Prevention of Cardiovascular Events

Emibe 10 is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin.

Homozygous Familial Hypercholesterolaemia (HoFH)

Emibe 10 co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).

Homozygous Sitosterolemia (Phytosterolemia) Emibe 10 is indicated as adjunctive therapy to diet for use in patients with homozy- gous familial sitosterolemia.

PACKAGING: 

Emibe 10 Tablet: Box containing 30 tablets in 3 x 10's blister strips.